Abbott’s Xience Stent Launch Drives Sales, Stock Gains In Third Quarter
This article was originally published in The Gray Sheet
Executive Summary
Abbott's Xience has become the leading drug-eluting coronary stent in the U.S. since its debut July 2, controlling a market share percentage in the "mid-to-upper 20s," according to the company
You may also be interested in...
J&J Orthopedic, Surgical Sales Help Offset 12% Cordis Decline In 2008
Sales in Johnson & Johnson's devices and diagnostics business in the fourth quarter were down in the U.S. and close to flat worldwide, with revenue from its DePuy orthopedic and Ethicon Endo-Surgery units offsetting a dismal performance from the Cordis franchise
J&J Orthopedic, Surgical Sales Help Offset 12% Cordis Decline In 2008
Sales in Johnson & Johnson's devices and diagnostics business in the fourth quarter were down in the U.S. and close to flat worldwide, with revenue from its DePuy orthopedic and Ethicon Endo-Surgery units offsetting a dismal performance from the Cordis franchise
Medtronic InFuse Sales Flat In Q2; Firm’s Spine Business Still Struggling
Medtronic is exploring alternative distribution channels in oral maxillofacial and trauma markets to grow its struggling InFuse bone graft franchise, the firm said during its Nov. 18 fiscal second-quarter earnings call